Stifel Initiates Coverage On Verve Therapeutics with Hold Rating, Announces Price Target of $58
Stifel analyst Dae Gon Ha initiates coverage on Verve Therapeutics (NASDAQ:VERV) with a Hold rating and announces Price Target of $58.
Verve Therapeutics’ Gene-Editing Therapy Shows Encouraging Preclinical Action In Cardiovascular Disease
Verve Therapeutics Inc (NASDAQ:VERV) has reported new preclinical data from 36 non-human primates (NHPs) with its lead candidate, VERVE-101. VERVE-101 is…
48 Biggest Movers From Friday
Gainers
Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS) shares jumped 135.4% to settle at $5.32 on Friday. The stock possibly traded higher following favorable data results by AstraZeneca for patients with unresectable, stage 3 non-small cell lung cancer.
The Daily Biotech Pulse: MacroGenics’ Clinical Trial Disappointment, Sanofi to Buy Kadmon, Alector Loses 2 Key Executives, ADMA’s FDA Nod
Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Sept. 7)
The Daily Biotech Pulse: VectivBio In M&A Mix, Sonnet Biotherapeutics Advances Candidate To Clinics, CEO Transitions At Galapagos, Talis Biomedical
Here's a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Aug. 26)
Verve Therapeutics Q2 EPS $(6.66) Down From $(3.41) YoY
Verve Therapeutics (NASDAQ:VERV) reported quarterly losses of $(6.66) per share. This is a 95.31 percent decrease over losses of $(3.41) per share from the same period last year.
Cathie Wood’s ARK Invest Posts Fund Purchases For Thursday, July 15, 2021: RPTX, VERV, FATE, SGFY, QSI, COIN, EXAS, U, KTOS, MKFG, PATH, CND, KVSB
Repare Therapeutics (RPTX) - 39,887 Shares
Verve Therapeutics (VERV) - 60,256
Fate Therapeutics (FATE) - 152,712
Signify Health (SGFY) - 36,732
Quantum-Si (QSI) - 347,305
Coinbase Global (COIN) - 69,172
Exact
Cathie Wood’s ARK Invest Posts Fund Purchases For Wednesday, July 14, 2021: FTCH, VERV, EXAS, FATE, SGFY, RPTX, PATH, QSI, COIN, U, KTOS, MELI, KVSB, CND
Farfetch (FTCH) - 77,832 Shares
Verve Therapeutics (VERV) - 80,425
Exact Sciences (EXAS) - 82,938
Fate Therapeutics (FATE) - 70,126
Signify Health (SGFY) - 99,674
Repare Therapeutics (RPTX) - 201,765
UiPath
William Blair Initiates Coverage On Verve Therapeutics with Outperform Rating, Announces Price Target of $92
William Blair analyst Raju Prasad initiates coverage on Verve Therapeutics (NASDAQ:VERV) with a Outperform rating and announces Price Target of $92.